Maintenance Dovitinib for Colorectal and Pancreas Cancer

Inclusion Criteria

• •Patients with a confirmed diagnosis of:
• •1. Stage 4 colon cancer either s/p metastasectomy or post-initial chemotherapy or maintenance "standard of care", either involving 5-fluorouracil/leucovorin (5-FU/LV) alone or continual bevacizumab alone. Patients in maintenance cohort must have had 2 consecutive CT scans showing stable disease and not be experiencing significant prior treatment-related toxicity above Grade 1.
• •2. Pancreas cancer, either s/p resection and adjuvant chemotherapy or locally advanced pancreas cancer s/p chemotherapy and radiation. Initial chemotherapy or radiation therapy may have been stopped between 2 weeks and 2 months prior to study start, and patients must have recovered from prior treatment related toxicity to grade 1 or less.
• •Prior surgery, including tumor resection or metastasectomy must have been performed at least 4 weeks prior to study enrollment.
• •No concomitant anti-cancer treatment is allowed
• •Age \>/= 18 years
• •Performance status of 0-1
• •Adequate hepatic, bone marrow, and renal function
• •Partial thromboplastin time (PTT) must be \</= 1.5 x upper normal limit of institution's normal range and INR (International Normalized Ratio) \< 1.5.
• •Life expectancy \>/= 4 months for maintenance cohorts and \>/= 6 months for adjuvant cohorts
• •Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment and must not be lactating.
• •Subject is capable of understanding and complying with protocol demands and able to sign and date the informed consent